Blue Water Vaccines Announces Appointment of Retired Deloitte Consulting Senior Managing Director Simon Tarsh to Board of Directors
August 22 2022 - 1:00PM
Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the
Company”), a biopharmaceutical company developing transformational
vaccines to address significant global health challenges, today
announced the appointment of Simon Tarsh, seasoned financial
consultant with experience in the life science industry, to its
board of directors at BWV’s annual meeting.
Mr. Tarsh brings over 40 years of experience in the financial
industry to the Company, most recently serving global clients as a
Senior Managing Director in the Finance and Enterprise Performance
Practice at Deloitte Consulting since 2007. He led a growing global
practice focused on Operational Transformation, including
supporting Carve Out transactions, joint ventures and hybrid
structures, both in the US and in international locations, such as
India, China, Eastern Europe and Latin America. Throughout his
career, he has supported high growth companies with their financial
operations as they globalized, advising them on their expansion
while balancing growth with appropriate controls.
“We are honored to welcome Mr. Tarsh to the Blue Water Vaccines
Board of Directors following his appointment at the BWV annual
meeting,” said Joseph Hernandez, Chairman and Chief Executive
Officer of Blue Water Vaccines. “His distinguished career in
accounting and financial consulting across many sectors, including
the life science industry, will be invaluable to our operations as
we continue to advance our vaccine pipeline and develop novel
vaccine candidates.”
Mr. Tarsh received a Bachelor of Science undergraduate degree in
Business and Administration from the University of Salford,
Manchester, UK in 1981, and an MBA from City University Business
School, London, UK in 1988. He is a Fellow of the Chartered
Institute of Management Accountants (1984), which is considered as
a CPA equivalent.
About Blue Water Vaccines
Blue Water Vaccines Inc. is a biopharmaceutical company focused
on developing transformational vaccines to address significant
health challenges globally. Headquartered in Cincinnati, OH, the
company holds the rights to proprietary technology developed at the
University of Oxford, Cincinnati Children's Hospital Medical
Center, and St. Jude Children's Hospital. The company is developing
a universal flu vaccine that will provide protection from all
virulent strains in addition to licensing a novel norovirus (NoV)
S&P nanoparticle versatile virus-like particle (VLP) vaccine
platform from Cincinnati Children’s to develop vaccines for
multiple infectious diseases, including norovirus/rotavirus and
malaria, among others. Additionally, Blue Water Vaccines is
developing a Streptococcus pneumoniae (pneumococcus) vaccine
candidate, designed to specifically prevent the highly infectious
middle ear infections, known as Acute Otitis Media (AOM), in
children. For more information, visit
www.bluewatervaccines.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as “anticipate,” “believe,” “forecast,”
“estimate,” “expect,” and “intend,” among others. These
forward-looking statements are based on BWV’s current expectations
and actual results could differ materially. There are a number of
factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. These factors
include, but are not limited to, risks related to the development
of BWV’s vaccine candidates; the failure to obtain FDA clearances
or approvals and noncompliance with FDA regulations; delays and
uncertainties caused by the global COVID-19 pandemic; risks related
to the timing and progress of clinical development of our product
candidates; our need for additional financing; uncertainties of
patent protection and litigation; uncertainties of government or
third party payor reimbursement; limited research and development
efforts and dependence upon third parties; and substantial
competition. As with any vaccine under development, there are
significant risks in the development, regulatory approval and
commercialization of new products. BWV does not undertake an
obligation to update or revise any forward-looking statement.
Investors should read the risk factors set forth in BWV’s Annual
Report on Form 10-K for the fiscal year ended December 31, 2021,
filed with the Securities and Exchange Commission (the “SEC”) on
March 31, 2022, Quarterly Report on Form 10-Q for the quarter ended
June 30, 2022, filed with the SEC on August 15, 2022 and periodic
reports filed with the SEC on or after the date thereof. All of
BWV’s forward-looking statements are expressly qualified by all
such risk factors and other cautionary statements. The information
set forth herein speaks only as of the date thereof.
Media Contact Information:Blue Water Media
RelationsTelephone: (646) 942-5591 Email:
Nic.Johnson@russopartnersllc.com
Investor Contact Information:Blue Water Investor RelationsEmail:
investors@bluewatervaccines.com
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Sep 2024 to Oct 2024
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Oct 2023 to Oct 2024